JP Morgan Chase
FMTX

JP Morgan Chase’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

JP Morgan Chase’s Portfolio FMTX Stock Details FMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-543,781
Closed -$10.8M – 7371
2022
Q3 		$10.8M Buy
543,781
+522,232
+2,423% +$6.89M ﹤0.01% 2091
2022
Q2 		$148K Sell
21,549
-114
-0.5% -$800 ﹤0.01% 5221
2022
Q1 		$202K Buy
21,663
+4,236
+24% +$45.1K ﹤0.01% 5190
2021
Q4 		$248K Sell
17,427
-5,727
-25% -$99.1K ﹤0.01% 5228
2021
Q3 		$536K Buy
23,154
+3,947
+21% +$93.3K ﹤0.01% 4678
2021
Q2 		$478K Buy
19,207
+3,389
+21% +$91.1K ﹤0.01% 4722
2021
Q1 		$444K Buy
15,818
+8,043
+103% +$290K ﹤0.01% 4747
2020
Q4 		$272K Buy
7,775
+1,767
+29% +$76.9K ﹤0.01% 4694
2020
Q3 		$298K Buy
+6,008
New +$243K ﹤0.01% 4194

JP Morgan Chase's FMTX Position: Q4 2022 in Review

JP Morgan Chase sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 543,781 shares — an estimated $10.8M sold.

JP Morgan Chase first reported a position in FMTX in Q3 2020 and held it in 9 quarters. The position peaked at $10.8M in Q3 2022. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

  • JP Morgan Chase reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • JP Morgan Chase sold 543,781 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $10.8M.
  • JP Morgan Chase first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
  • JP Morgan Chase's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $10.8M in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.